Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392382 | 0.83 | CYP2A6 (0.34) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL14392561 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRGAAMEN1KMT2A | |
| SCHEMBL679133 | 0.77 | KMT2A (0.38) | NOTUMALDH1A1GAAPDK2PDK4 | |
| SCHEMBL14392374 | 0.76 | RARB (0.43) | ALDH1A1TSHRGAAPDK2MEN1 | |
| SCHEMBL16264924 | 0.75 | MAPT (0.40) | ALDH1A1TSHRMEN1KMT2AHPGD | |
| SCHEMBL14392799 | 0.74 | PDK2 (0.33) | NOTUMALDH1A1GAAPDK2PDK4 | |
| SCHEMBL676795 | 0.74 | PDK2 (0.38) | NOTUMPDK2PDK4KDM4EMAPT | |
| SCHEMBL14392370 | 0.74 | GAA (0.35) | ALDH1A1TSHRGAAMEN1KMT2A | |
| SCHEMBL14369407 | 0.72 | NOTUM (0.47) | NOTUMGAAMEN1KMT2AMAPK1 | |
| SCHEMBL18620881 | 0.72 | LMNA (0.38) | ALDH1A1GAAPDK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458522-B1 | PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY | ICROM SPA (IT) | 2024-01-03 | — | — | EP | claimed |
| US-20230372410-A1 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders | LABYRINTH HOLDINGS LLC | 2023-11-23 | — | — | US | claimed |
| US-10723710-B2 | Process for the preparation of diaminophenothiazinium compounds having a high degree of purity | ICROM S.P.A. (IT) | 2020-07-28 | — | — | US | claimed |
| US-20190210969-A1 | INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-07-11 | — | — | US | claimed |
| US-20190185440-A1 | PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY | ICROM S.P.A. (IT) | 2019-06-20 | — | — | US | claimed |
| US-9856364-B2 | Stabilized reversible polymer composition | XEROX CORPORATION (US) | 2018-01-02 | — | — | US | claimed |
| US-20140353549-A1 | STABILIZED REVERSIBLE POLYMER COMPOSITION | XEROX CORPORATION (US) | 2014-12-04 | — | — | US | claimed |
| EP-2328875-B1 | TARGETED NITROXIDE AGENTS | UNIV PITTSBURGH (US) | 2014-10-15 | — | — | EP | claimed |
| US-8822541-B2 | Use of targeted nitroxide agents in mitigating or treating radiation injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-09-02 | — | — | US | claimed |
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-08-16 | — | — | US | claimed |
| WO-2010009389-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-01-21 | — | — | WO | claimed |
| EP-0845448-B1 | Inhibiting polymerization of vinyl aromatic monomers | ONDEO NALCO ENERGY SERV LP (US) | 2002-01-30 | — | — | EP | claimed |
| US-6117276-A | INCORPORATING TO THE VINYL AROMATIC MONOMER AN EFFECTIVE AMOUNT OF ACTIVATED NITROXYL-VINYL AROMATIC MONOMER MIXTURE WHICH IS CAPABLE OF INHIBITING PREMATURE POLYMERIZATION OF MONOMERS DURING DISTILLATION AND PURIFICATION | NALCO/EXXON ENERGY CHEMICALS, L.P. (US) | 2000-09-12 | — | — | US | claimed |
| US-5952826-A | A DIMETHYL ETHERS SOLVENT WITH A DISSOLVED NITROXIDE RADICAL FOR IMPROVING THE STABILITY AND RESISTANCE TO MAGNETIC FIELD GRADIENTS OVER A WIDE TEMPERATURE RANGE, DYNAMIC POLARIZATION | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1999-09-14 | — | — | US | claimed |
| EP-0845448-A1 | Inhibiting polymerization of vinyl aromatic monomers | Ciba SC Holding AG (CH) | 1998-06-03 | — | — | EP | claimed |
| US-5681753-A | Solution containing a nitroxide radical for magnetometry by nuclear magnetic resonance | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1997-10-28 | — | — | US | claimed |
| EP-0780697-A1 | Solution for radicals for an NMR magnetometer | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1997-06-25 | — | — | EP | claimed |
| EP-0717054-A2 | Stable free radical polymerization process and thermoplastic materials produced therefrom | XEROX CORPORATION (US) | 1996-06-19 | — | — | EP | claimed |
| EP-0716063-A1 | Solution containing a nitroxide radical for magnetometry by nuclear magnetic resonance | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1996-06-12 | — | — | EP | claimed |
| US-5449724-A | Stable free radical polymerization process and thermoplastic materials produced therefrom | XEROX CORPORATION (US) | 1995-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210969-A1 | INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS | HSPE1, HSPA9, HSPD1 | NOTUM 3562/4885ALDH1A1 1888/4885TSHR 2990/4885 |
| US-10723710-B2 | Process for the preparation of diaminophenothiazinium compounds having a high degree of purity | DDT, QDPR, DDC | NOTUM 2435/4885ALDH1A1 1676/4885TSHR 3189/4885 |
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | NOX1, OGG1, NOX5 | NOTUM 917/4885ALDH1A1 1100/4885TSHR 4805/4885 |
| US-20190185440-A1 | PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY | DDT, QDPR, DDC | NOTUM 2435/4885ALDH1A1 1676/4885TSHR 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.